Johnson & Johnson looking to buy Ollin Biosciences for up to US$3.4bil
Verified: 2 outlets in 2 countries have reported this story since Nov 16.
NEW YORK: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to US$3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
How sure are we
Two or more outlets reported this story and its reliability score reached 65%, so WorldPulse marks it verified. That means more than one outlet says so, not that it is proven true.
Who reported it
- Nov 16, 1:18 AM UTCFirst report· you’re reading thisJohnson & Johnson looking to buy Ollin Biosciences for up to US$3.4bilnst.com.my ↗
- Nov 16, 3:19 AM UTC+2 hJ&J looks to buy Ollin Biosciences for up to $3.4 billion, FT saysinvesting.com ↗
- Verified: a second independent outlet reported itNov 16, 3:19 AM UTC · +2 h
[Claude] Report 2 covers the same FT-reported J&J deal to buy Ollin Biosciences for up to $3.4 billion, with matching details.
12m agoScore bands
What moves the score
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this